Watson CEO Claims FTC Pressured Company To Allow Apotex To Market Generic Provigil
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson CEO Paul Bisaro is fighting an FTC subpoena to testify in the commission's investigation of a reverse settlement agreement involving Cephalon's Provigil.
You may also be interested in...
Watson CEO Bisaro Ordered To Comply With FTC Subpoena
Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.
Watson CEO Bisaro Ordered To Comply With FTC Subpoena
Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.
Watson Gets To Investigate FTC Communications With FDA After Discovery Ruling
A federal judge says the facts show "the strong possibility" that FTC tried to broker a deal between Watson and Apotex requiring Watson to give up its marketing exclusivity for generic Provigil.